Tesaro is an oncology-focused company that aims to help improve the lives of cancer patients. It's first drug, Rolapitant, was licensed from Opko Health ( OPK) for a terrific price and is now in Phase III testing. That drug helps prevent nausea in patients undergoing chemotherapy. Tesaro also has two other drugs in early stage testing, one to directly attack tumors and the other to treat specific lung cancers. With over $138 million in cash on its books and no debt, Cramer said that Tesaro is really a $10 stock with a very promising future.